Role of biofilm formation in ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 394-398

  Pandelidis, Katherine ^a   McCarthy, Amanda ^a   Chesko, Kirsty L ^a   Viscardi, Rose M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Azithromycin; Bacterial bio films; Bronchopulmonary dysplasia; Erythromycin; Ureaplasma parvum; Ureaplasma urealyticum

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; IMMUNE RESPONSE; IN VITRO STUDY; LUNG DYSPLASIA; PREMATURITY; PRIORITY JOURNAL; UREAPLASMA; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM;

ANTI-BACTERIAL AGENTS; BIOFILMS; BRONCHOPULMONARY DYSPLASIA; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MICROBIAL SENSITIVITY TESTS; UREAPLASMA INFECTIONS; UREAPLASMA UREALYTICUM;

EID: 84876283428     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182791ae0     Document Type: Article

References (45)

1. Volgmann T, Ohlinger R, Panzig B. Ureaplasma urealyticum-harmless commensal or underestimated enemy of human reproduction? A review. Arch Gynecol Obstet. 2005;273:133-139.
2. Viscardi RM. Ureaplasma species: role in diseases of prematurity. Clin Perinatol. 2010;37:393-409.
3. Oh KJ, Lee SE, Jung H, et al. Detection of Ureaplasmas by the polymerase chain reaction in the amniotic fluid of patients with cervical insufficiency. J Perinat Med. 2010;38:261-268.
4. Namba F, Hasegawa T, Nakayama M, et al. Placental features of chorioam-nionitis colonized with Ureaplasma species in preterm delivery. Pediatr Res. 2010;67:166-172.
5. Goldenberg RL, Andrews WW, Goepfert AR, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol. 2008;198:43.e1-43.e5.
6. Viscardi RM, Hashmi N, Gross GW, et al. Incidence of invasive Ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage. J Perinatol. 2008;28:759-765.
7. Hassanein SM, El-Farrash RA, Hafez HM, et al. Cord blood interleukin-6 and neonatal morbidities among preterm infants with PCR-positive urea-plasma urealyticum. J Matern Fetal Neonatal Med. 2012;25:2106-2110.
8. Sung TJ, Xiao L, Duffy L, et al. Frequency of Ureaplasma serovars in respiratory secretions of preterm infants at risk for bronchopulmonary dysplasia. Pediatr Infect Dis J. 2011;30:379-383.
9. Oue S, Hiroi M, Ogawa S, et al. Association of gastric fluid microbes at birth with severe bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed. 2009;94:F17-F22.
10. Wang EE, Cassell GH, Sánchez PJ, et al. Ureaplasma urealyticum and chronic lung disease of prematurity: critical appraisal of the literature on causation. Clin Infect Dis. 1993;17(suppl 1):S112-S116.
11. Schelonka RL, Katz B, Waites KB, et al. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaana-lytic techniques. Pediatr Infect Dis J. 2005;24:1033-1039.
12. Okogbule-Wonodi AC, Gross GW, Sun CC, et al. Necrotizing enterocolitis is associated with Ureaplasma colonization in preterm infants. Pediatr Res. 2011;69(5 Pt 1):442-447.
13. Clifford V, Tebruegge M, Everest N, et al. Ureaplasma: pathogen or passenger in neonatal meningitis? Pediatr Infect Dis J. 2010;29:60-64.
14. Renaudin H, Bébéar C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis. 1990;9:83 8-841.
15. Ogasawara KK, Goodwin TM. The efficacy of prophylactic erythromycin in preventing vertical transmission of Ureaplasma urealyticum. Am J Perinatol. 1997;14:233-237.
16. Ogasawara KK, Goodwin TM. Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J Matern Fetal Med. 1999;8:12-16.
17. Dando SJ, Nitsos I, Newnham JP, et al. Maternal administration of erythromycin fails to eradicate intrauterine Ureaplasma infection in an ovine model. Biol Reprod. 2010;83:616-622.
18. Bowman ED, Dharmalingam A, Fan WQ, et al. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J. 1998;17:615-620.
19. Jónsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr. 1998;87:1079-1084.
20. Lyon AJ, McColm J, Middlemist L, et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;78:F10-F14.
21. Baier RJ, Loggins J, Kruger TE. Failure of erythromycin to eliminate airway colonization with Ureaplasma urealyticum in very low birth weight infants. BMC Pediatr. 2003;3:10.
22. Mabanta CG, Pryhuber GS, Weinberg GA, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev. 2003:CD003744.
23. Mhanna MJ, Delong LJ, Aziz HF The value of Ureaplasma urealyticum tracheal culture and treatment in premature infants following an acute respiratory deterioration. J Perinatol. 2003;23:541-544.
24. Ballard HO, Shook LA, Bernard P, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr Pulmonol. 2011;46:111-118.
25. Simmons WL, Dybvig K. Mycoplasma biofilms ex vivo and in vivo. FEMS Microbiol Lett. 2009;295:77-81.
26. McAuliffe L, Ellis RJ, Miles K, et al. Biofilm formation by mycoplasma species and its role in environmental persistence and survival. Microbiology (Reading, Engl). 2006;152(Pt 4):913-922.
27. Simmons WL, Bolland JR, Daubenspeck JM, et al. A stochastic mechanism for biofilm formation by Mycoplasma pulmonis. J Bacteriol. 2007;189:1905-1913.
28. Simmons WL, Dybvig K. Biofilms protect Mycoplasma pulmonis cells from lytic effects of complement and gramicidin. Infect Immun. 2007;75:3696-3699.
29. Kornspan JD, Tarshis M, Rottem S. Adhesion and biofilm formation of Mycoplasma pneumoniae on an abiotic surface. Arch Microbiol. 2011;193:833-836.
30. García-Castillo M, Morosini MI, Gálvez M, et al. Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J Antimicrob Chemother. 2008;62:1027-1030.
31. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-1729.
32. Naessens A, Foulon W, Breynaert J, et al. Serotypes of Ureaplasma urealyticum isolated from normal pregnant women and patients with pregnancy complications. J Clin Microbiol. 1988;26:319-322.
33. Quinn PA, Shewchuk AB, Shuber J, et al. Serologic evidence of Ureaplasma urealyticum infection in women with spontaneous pregnancy loss. Am J Obstet Gynecol. 1983;145:245-250.
34. Quinn PA, Li HC, Th'ng C, et al. Serological response to Ureaplasma urealyticum in the neonate. Clin Infect Dis. 1993;17(suppl 1):S136-S143.
35. Xiao L, Glass JI, Paralanov V, et al. Detection and characterization of human Ureaplasma species and serovars by real-time PCR J Clin Microbiol. 2010;48:2715-2723.
36. Nickel JC, Costerton JW, McLean RJ, et al. Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J Antimicrob Chemother. 1994;33(suppl A):31-41.
37. Romero R, Schaudinn C, Kusanovic JP, et al. Detection of a microbial biofilm in intraamniotic infection. Am J Obstet Gynecol. 2008;198:135.e1-135. e5.
38. Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect. 2010;16:1649-1655.
39. Kenny GE, Cartwright FD Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinu-pristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45:2604-2608.
40. Waites KB, Crabb DM, Bing X, et al. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2003;47:161-165.
41. Waites KB, Figarola TA, Schmid T, et al. Comparison of agar versus broth dilution techniques for determining antibiotic susceptibilities of Ureaplasma urealyticum. Diagn Microbiol Infect Dis. 1991;14:265-271.
42. Kenny GE, Cartwright FD. Effect of pH, inoculum size, and incubation time on the susceptibility of Ureaplasma urealyticum to erythromycin in vitro. Clin Infect Dis. 1993;17(suppl 1):S215-S218.
43. Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother. 2011;23:77-79.
44. Walls SA, Kong L, Leeming HA, et al. Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice. Pediatr Res. 2009;66:197-202.
45. Hassan HE, Othman AA, Eddington ND, et al. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for Ureaplasma colonization and bronchopulmonary dysplasia. J Clin Pharmacol. 2011;51:1264-1275.